object
evalu
scientif
basi
use
kang
heji
antiinflammatori
antipyret
agent
use
appropri
anim
model
method
carrageenaninduc
rat
paw
xyleneinduc
ear
oedema
model
use
investig
antiinflammatori
action
lipopolysaccharideinduc
pyrexia
model
use
evalu
antipyret
activ
wistar
rat
antiinflammatori
antipyret
mechan
evalu
detect
prostaglandin
e
nitric
oxid
tumour
necrosi
factora
level
use
appropri
reagent
elisa
kit
result
result
reveal
reduc
level
inflamm
antiinflammatori
model
dosedepend
manner
true
antipyret
model
possibl
mechan
action
inhibit
prostaglandin
e
tumour
necrosi
factora
nitric
oxid
conclus
proven
antiinflammatori
antipyret
action
find
provid
scientif
basi
use
antiinflammatori
antipyret
agent
tradit
chines
medicin
practic
inflamm
defin
biolog
respons
bodi
local
injuri
infect
character
red
oedema
fever
pain
loss
function
involv
cascad
event
elicit
numer
stimuli
includ
infecti
agent
ischaemia
thermal
physic
injuri
antigenantibodi
interact
even
though
inflamm
defenc
mechan
bodi
elimin
limit
spread
injuri
stimuli
heal
wound
excess
inflamm
associ
onset
diseas
like
rheumatoid
arthriti
asthma
periodont
inflammatori
bowel
diseas
atherosclerosi
alzheim
diseas
even
cancer
gall
bladder
carcinoma
nonsteroid
antiinflammatori
drug
wide
use
treatment
acut
chronic
inflamm
pain
fever
use
associ
advers
effect
like
sever
gastriti
peptic
ulcer
nausea
vomit
salt
water
retent
worsen
renal
function
renal
cardiac
cirrhot
patient
hypersensit
etc
therefor
need
screen
develop
antiinflammatori
drug
devoid
unwant
effect
herbal
medicin
lack
side
effect
current
trend
conduct
investig
plantbas
drug
accord
world
health
organ
world
popul
still
reli
mainli
tradit
herbal
remedi
fever
regul
rise
bodi
temperatur
normal
rang
usual
consid
sign
infect
though
defenc
mechan
sustain
fever
potenti
harm
effect
dehydr
delirium
convuls
cardiopulmonari
strain
local
lesion
teratolog
consequ
common
caus
fever
bacteri
infect
mimick
experiment
system
inject
lipopolysaccharid
lp
lp
major
compon
gramneg
bacteri
cell
wall
induct
fever
involv
array
cytokin
tumour
necrosi
factora
tnfa
etc
mediat
lead
product
prostaglandin
e
pge
kang
heji
tradit
chines
remedi
common
cold
compris
five
herb
lonicera
japonica
thunb
l
japonica
isati
indigotica
fort
indigotica
rheum
palmatum
l
phellodendron
chinens
schneid
p
chinens
scutellaria
baicalensi
georgi
baicalensi
usual
use
due
abil
allevi
symptom
common
cold
headach
fever
inflamm
gener
bodili
pain
etc
though
data
scientif
literatur
provid
inform
individu
herb
formul
scientif
evid
avail
uniqu
formul
justifi
use
aim
work
investig
antiinflammatori
antipyret
properti
formul
use
appropri
anim
model
work
also
aim
identifi
chemic
makeup
formul
could
help
explain
possibl
mechan
action
purchas
nanj
children
hospit
indomethacin
shaanxi
yuupeng
pharm
co
ltd
dexamethason
jinan
limin
pharmaceut
co
ltd
use
studi
steril
normal
salin
solut
purchas
anhui
shuangh
pharmaceut
co
ltd
lp
escherichia
coli
purchas
sigmaaldrich
carrageenan
bought
aladdin
chemistri
co
ltd
high
perform
liquid
chromatographi
grade
acetonitril
purchas
merck
darmstadt
germani
distil
water
purifi
milliq
system
millipor
usa
high
perform
liquid
chromatographi
grade
methanol
gotten
jiangsu
hanbon
sci
tech
co
ltd
jiangsu
china
analyt
grade
formic
acid
purchas
nanj
chemic
factori
nanj
china
kit
elisa
purchas
cusabio
biotech
co
ltd
wuhan
china
ml
dissolv
ml
distil
water
result
solut
centrifug
rmin
min
supernat
transfer
sampl
vial
ultra
perform
liquid
chromatographymass
spectromet
uplcm
analysi
chromatograph
analysi
perform
agil
seri
agil
corp
santa
clara
ca
usa
uplc
system
equip
binari
pump
micro
degass
auto
sampler
thermostat
control
column
compart
chromatograph
separ
carri
c
zorbax
rrhd
eclips
plu
c
column
mm
mm
mm
mobil
phase
consist
formic
acid
solut
acetonitril
b
use
gradient
elut
b
min
b
min
b
min
b
min
min
min
min
flow
rate
kept
mlmin
sampl
volum
inject
set
ml
detect
carri
agil
qtof
mass
spectromet
agil
corp
santa
clara
ca
usa
equip
electrospray
ioniz
interfac
paramet
oper
follow
dri
ga
n
flow
rate
lmin
temperatur
c
nebul
psig
capillari
v
skimmer
v
oct
rfv
v
sampl
analyz
posit
neg
mode
due
select
sensit
differ
compon
formulationprovid
better
inform
molecular
formula
structur
identif
mass
spectra
record
across
rang
mz
accur
mass
measur
male
wistar
albino
rat
yangzhou
univers
cooper
medicin
center
weigh
g
use
studi
hous
acryl
fibr
cage
c
humid
kept
h
lightdark
cycl
fed
standard
pellet
diet
jiangsu
provinci
synergist
engin
co
ltd
water
ad
libitum
anim
made
acclimat
new
environ
day
experiment
fast
h
test
anim
care
use
compli
provis
gener
recommend
chines
experiment
anim
administr
legisl
experi
perform
approv
anim
ethic
committe
china
pharmaceut
univers
carrageenaninduc
paw
oedema
one
model
use
evalu
antiinflammatori
effect
describ
winter
et
al
modif
baselin
valu
paw
volum
taken
h
use
plethysmomet
total
rat
divid
six
group
eight
rat
group
drug
administ
follow
manner
group
receiv
ml
distil
water
neg
control
group
receiv
mgkg
indomethacin
posit
control
group
receiv
mgkg
mgkg
mg
kg
respect
group
receiv
normal
salin
h
ml
carrageenan
normal
salin
inject
subcutan
tissu
right
hind
paw
anim
paw
volum
measur
h
oedema
express
mean
increas
paw
volum
rel
control
anim
percentag
inhibit
oedema
calcul
use
follow
equat
v
paw
volum
h
v
paw
volum
h
six
group
n
rat
treat
follow
group
receiv
mgkg
mgkg
mg
kg
bodi
weight
group
receiv
mgkg
indomethacin
group
receiv
mgkg
dexamethason
ip
group
receiv
normal
salin
neg
control
administr
drug
min
anim
receiv
ml
xylen
anterior
posterior
surfac
right
ear
left
ear
consid
normal
control
anoth
min
anim
sacrif
ear
sampl
punch
mm
diamet
weigh
extent
oedema
evalu
weight
differ
right
left
ear
biopsi
anim
anim
randomli
divid
six
group
n
anim
group
receiv
mgkg
bodi
weight
drug
gavag
group
anim
receiv
mgkg
bodi
weight
indomethacin
anim
group
receiv
mgkg
bodi
weight
dexamethason
via
intraperiton
inject
anim
group
receiv
vehicl
pyrogenfre
water
min
anim
group
receiv
pyrogenfre
steril
normal
salin
solut
group
inject
intraperiton
lp
mgkg
dissolv
pyrogenfre
steril
normal
salin
solut
bodi
temperatur
tb
taken
everi
h
h
lp
administr
experi
perform
light
phase
circadian
cycl
tb
measur
gentli
insert
small
thermoprob
cm
rectum
beep
sound
heard
temperatur
measur
anim
held
gentli
perform
least
twice
day
prior
experi
avoid
chang
rectal
temperatur
secondari
handl
anim
stabl
bodi
temperatur
rang
c
use
investig
influenc
drug
tb
anim
upon
induct
pyrexia
lp
mechan
activ
test
cytokin
tnfa
pge
tnfa
pge
level
supernat
measur
use
elisa
kit
cusabio
biotech
co
ltd
wuhan
china
accord
manufactur
instruct
briefli
dilut
standard
sampl
ad
plate
precoat
affin
purifi
polyclon
antibodi
specif
rat
tnfa
pge
well
enzymelink
polyclon
antibodi
ad
incub
c
min
wash
time
addit
substrat
solut
intens
detect
nm
proport
product
tnfa
pge
amount
nitrit
indic
product
measur
use
griess
reagent
brief
supernat
plasma
anim
model
mix
volum
griess
reagent
b
incub
room
temperatur
min
dark
place
absorb
measur
nm
use
biotek
synergi
spectrophotomet
biopsi
right
hind
paw
rat
collect
induct
inflamm
carrageenan
h
tissu
slice
fix
formalinacet
acid
fix
formalin
acet
acid
room
temperatur
dehydr
embed
paraffin
section
mm
tissu
section
stain
haematoxylin
eosin
examin
olympu
japan
microscop
tissu
slice
randomli
taken
paw
rat
follow
group
indomethacin
posit
control
group
group
receiv
highest
dose
mgkg
bodi
weight
model
group
well
rat
given
carrageenan
inject
neg
control
result
express
mean
sem
differ
control
treatment
group
analyz
use
oneway
analysi
varianc
anova
graphpad
prism
softwar
describ
dunnett
test
p
consid
signific
p
consid
signific
p
consid
highli
signific
use
strategi
develop
lab
compound
tent
identifi
uplcqtofm
retent
time
ms
data
character
compound
summar
tabl
paw
size
increas
steadili
peak
h
inject
carrageenan
seen
clearli
neg
control
group
variou
dose
reduc
paw
size
time
point
dosedepend
manner
highest
dose
mgkg
even
prove
effect
reduc
inflamm
h
control
drug
indomethacin
shown
figur
effect
drug
reduct
ear
size
rat
upon
induct
oedema
xylen
investig
model
vari
dose
mgkg
bodi
weight
formul
given
effect
compar
two
posit
control
indomethacin
dexamethason
neg
control
figur
illustr
outcom
bar
chart
effect
formul
dosedepend
mgkg
bodi
weight
give
highest
level
inhibit
thu
lowest
weight
inflam
ear
two
posit
control
exhibit
compar
effect
dexamethason
give
higher
inhibit
rate
inhibit
rate
compar
control
group
gave
pvalu
follow
p
p
p
respect
mgkg
mgkg
posit
control
respect
lpsinduc
fever
peak
h
inject
reduct
bodi
temperatur
also
dosedepend
use
mgkg
bodi
weight
give
maximum
effect
high
dose
howev
effect
posit
control
indomethacin
dexamethason
dexamethason
mgkg
prove
littl
effect
indomethacin
reduc
bodi
temperatur
h
experiment
probabl
due
fact
given
ip
shown
figur
histopatholog
result
shown
figur
show
cellular
infiltr
oedema
control
group
figur
contrast
polymorphonuclear
infiltr
swell
follow
carrageenan
inject
figur
treatment
mgkg
signific
reduct
polymorphonuclear
infiltr
oedema
shown
figur
compar
standard
control
drug
indomethacin
figur
tent
identif
compound
could
arduou
task
especi
refer
compound
avail
refer
compound
similar
compound
could
identifi
base
retent
time
fragment
pattern
data
literatur
absenc
refer
compound
lot
strategi
employ
tent
identif
structur
confirm
strategi
employ
identif
method
call
diagnost
ion
filter
strategi
briefli
diagnost
ion
correspond
mother
skeleton
obtain
refer
compound
use
screen
type
compound
molecular
ion
screen
peak
calcul
use
neg
posit
ion
mode
next
accur
molecular
formula
peak
obtain
appli
screen
hit
variou
chemic
databas
possibl
structur
contain
substructur
substitu
group
determin
candid
comparison
characterist
product
ion
fragment
pathway
outcom
identif
constitu
formul
reveal
contain
varieti
compound
rang
flavonoid
isoflavonoid
alkaloid
etc
total
compound
tent
identifi
posit
neg
ion
mode
identif
chemic
makeup
formul
prove
use
explain
possibl
mechan
action
carrageenaninduc
paw
oedema
good
reliabl
repeat
vivo
experiment
model
employ
investig
antiinflammatori
agent
follow
carrageenan
inject
develop
oedema
believ
biphas
eventu
lead
sign
inflamm
oedema
hyperalgesia
erythema
earli
phase
involv
releas
inflammatori
mediat
histamin
serotonin
bradykinin
late
phase
associ
releas
prostaglandin
also
known
platelet
activ
factor
arachidon
acid
metabolit
play
vital
role
phase
inflamm
result
effect
lead
increas
vascular
permeabl
enhanc
infiltr
neutrophil
accumul
plasma
fluid
interstiti
space
lead
oedema
result
studi
reveal
inflamm
inhibit
phase
though
latter
phase
show
signific
also
reveal
level
inhibit
inflamm
dosedepend
dose
mgkg
bodi
weight
gave
better
result
term
reduct
inflamm
compar
control
drug
indomethacin
time
h
h
h
xyleneinduc
ear
oedema
anoth
inflamm
model
use
xylen
wellknown
inflammatori
agent
provok
acut
inflammatori
respons
ear
rat
lead
seriou
oedemat
chang
skin
appli
ear
acut
inflammatori
respons
sever
vasodil
oedemat
chang
skin
partial
associ
phospholipas
report
lubernarod
et
al
kim
et
al
wang
et
al
formul
also
reduc
inflamm
ear
rat
dosedepend
manner
mgkg
give
highest
outcom
fever
commonli
studi
laboratori
inject
anim
bacteri
lp
mediat
action
proinflammatori
cytokin
tnfa
report
lpsinduc
fever
rat
polyphas
differ
underli
mechan
respons
anim
fever
depend
serotyp
dose
lp
inject
rout
stress
ambient
temperatur
anim
strain
gender
differ
tb
anim
increas
h
inject
lp
peak
h
h
though
underli
process
fever
initi
susten
multipl
vari
complex
believ
lp
caus
fever
stimul
peripher
macrophag
synthes
releas
pyrogen
cytokin
tnfa
cytokin
transport
thermoregulatori
centr
anterior
hypothalamu
consequ
stimul
product
pge
pge
ultim
lead
elev
temperatur
henc
fever
pge
major
mediat
fever
present
phase
polyphas
lpsinduc
fever
also
found
part
sever
system
involv
tb
regul
act
peripher
found
pyret
investig
potenti
antipyret
agent
found
possess
abil
reduc
fever
also
dosedepend
manner
shown
figur
effect
howev
even
high
dose
mgkg
bodi
weight
though
signific
h
could
compar
posit
control
dexamethason
indomethacin
possibl
mechan
action
formul
could
due
inhibit
product
inhibit
cytokin
releas
well
inhibit
pge
releas
inflamm
variou
phase
lpsinduc
pyrexia
probabl
reason
activ
antiinflammatori
antipyret
agent
could
trace
back
composit
earlier
mention
formul
contain
flavonoid
isoflavonoid
alkaloid
etc
flavonoid
found
antioxid
free
radic
scaveng
activ
could
regul
cellular
activ
inflammationrel
cell
thu
mast
cell
macrophag
lymphocyt
neutrophil
certain
flavonoid
modul
enzym
activ
arachidon
acid
metabol
enzym
phospholipas
cyclooxygenas
lipoxygenas
produc
enzym
synthas
therefor
inhibit
enzym
flavonoid
lead
reduc
product
arachidon
acid
prostaglandin
leukotrien
crucial
mediat
inflamm
anoth
antiinflammatori
properti
flavonoid
abil
inhibit
nuclear
factor
kappa
b
transcript
activ
alkaloid
also
found
good
antiinflammatori
agent
instanc
indol
alkaloid
root
indigotica
found
inhibitori
effect
product
alkaloid
fraction
alstonia
scholari
includ
picrinin
vallesamin
scholaricin
also
found
inhibit
prostaglandin
pge
product
variou
alkaloid
therefor
exhibit
activ
via
differ
mechan
histopatholog
analys
also
show
extent
could
amelior
inflamm
mgkg
bodi
weight
prove
effect
prevent
polymorphonuclear
infiltr
site
inflamm
paw
compar
favour
control
drug
indomethacin
herbal
formul
found
contain
bioactiv
compound
usual
act
synergi
give
desir
pharmacolog
effect
thu
effect
formul
could
due
differ
compound
act
conson
necessarili
one
specif
compound
find
howev
agreement
research
work
individu
compon
formul
l
japonica
commonli
use
treatment
sore
carbuncl
furuncl
swell
infect
caus
exopathogen
windheat
epidem
febril
diseas
earli
stage
life
also
found
hepatoprotect
cytoprotect
antimicrobi
antioxid
antivir
antiinflammatori
effect
indigotica
found
use
prevent
treat
influenza
tonsil
malign
infecti
diseas
especi
sever
acut
respiratori
syndrom
antivir
antibacteri
antiinflammatori
antitumour
immun
regulatori
function
p
chinens
wellknown
orient
folk
medicin
effect
antiinflammatori
antiphlogist
antipyret
agent
clinic
usag
baicalensi
tradit
use
treatment
inflamm
asthma
well
throat
disord
eg
cough
tonsil
pharyng
combin
effect
compon
thu
investig
conclus
formul
found
possess
antiinflammatori
antipyret
activ
found
inhibit
product
releas
cytokin
tnfa
pge
outcom
research
provid
solid
foundat
pharmacolog
studi
uniqu
formul
actual
ongo
declar
conflict
interest
